Home > News > Sodium–Glucose Co-transporter 2 Inhibition—A Novel Strategy for Glucose Control in Type 2 Diabetes
Diabetes
Read Time: 13 mins

Sodium–Glucose Co-transporter 2 Inhibition—A Novel Strategy for Glucose Control in Type 2 Diabetes

Published Online: June 6th 2011 US Endocrinology, 2010;6(1):42-47 DOI: http://doi.org/10.17925/USE.2010.06.1.42
Authors: Luke Norton, Ralph A DeFronzo, Muhammad A Abdul-Ghani
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Abstract
In addition to its central role in the development of microvascular complications, hyperglycemia plays an important role in the pathogenesis of type 2 diabetes, i.e. glucotoxicity. Thus, effective glycemic control not only reduces the incidence of microvascular complications, but also corrects the metabolic abnormalities that contribute to the progression of the disease. Progressive beta-cell failure and side effects associated with therapy, such as hypoglycemia and weight gain, present obstacles to the achievement of optimal durable glycemic control in subjects with type 2 diabetes. Most recently, inhibitors of the renal sodium glucose co-transporter have been developed to produce glucosuria and reduce the plasma glucose concentration. Because the mechanism of action of these oral antidiabetic agents is independent of beta-cell and tissue sensitivity to insulin, they improve glycemic control while avoiding hypoglycemia and promoting weight loss. In this article, we will summarize the available data concerning the mechanism of action, efficacy, and safety of this novel antidiabetic therapeutic approach.

Keywords
Type 2 diabetes, kidney, sodium–glucose co-transport, sodium–glucose co-transporter 2 (SGLT2) inhibition

Disclosure: Luke Norton, PhD, and Muhammad A Abdul-Ghani, MD, PhD, have no conflicts of interest to declare. Ralph A DeFronzo, MD, has received research grants from Takeda, Amylin, and Eli Lilly, has acted as a consultant to Amylin, Takeda, Novartis, and ISIS, and has served on advisory boards for Takeda and Amylin.
Received: August 13, 2010 Accepted: October 29, 2010 Citation: US Endocrinology, 2010;6:42–7
Correspondence: Muhammad A Abdul-Ghani, MD, PhD, Division of Diabetes, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, Texas 78229. E: albarado@uthscsa.edu

Article:

Individuals with type 2 diabetes suffer from increased morbidity and mortality secondary to both macrovascular (heart attack, stroke, and amputation)1 and microvascular (retinopathy, nephropathy, and neuropathy)2 complications. Hyperglycemia is the major risk factor for microvascular complications.

Individuals with type 2 diabetes suffer from increased morbidity and mortality secondary to both macrovascular (heart attack, stroke, and amputation)1 and microvascular (retinopathy, nephropathy, and neuropathy)2 complications. Hyperglycemia is the major risk factor for microvascular complications.

Many studies, e.g. the Diabetes Control and Complications Trial (DCCT)3 and the UK Prospective Diabetes Study (UKPDS),4 have documented that correcting the hyperglycemia reduces the risk of microvascular complication. Every 1% decrease in glycated hemoglobin (HbA1c) is associated with ~35% reduction in microvascular complications.4,5 Insulin resistance and progressive beta-cell failure represent the two core defects that characterize subjects with type 2 diabetes.5 Hyperglycemia plays an importantl role in the pathogenesis of insulin resistance and beta-cell failure, i.e. glucotoxicity.6 Thus, appropriate glycemic control in diabetic subjects would be anticipated to reduce the risk of microvascular complications and ameliorate the metabolic abnormalities that contribute to the progressive course of the disease. Thus, tight glycemic control has become the cornerstone of management in subjects with type 2 diabetes and all professional organizations recommend that HbA1c should be maintained at ≤6.5–7%.7–10 Progressive beta-cell failure, weight gain, and hypoglycemia represent major obstacles for the achievement of tight glycemic control and HbA1c ≤6.5–7% in patients with type 2 diabetes.3 Therefore, the development of novel medications that effectively lower the plasma glucose level, produce durable glycemic control, and are not associated with hypoglycemia and weight gain are needed for the management of type 2 diabetes patients. Most recently, inhibitors of the renal sodium glucose co-transporter have been developed to produce glucosuria and reduce the plasma glucose concentration. In this article we will summarize the available data concerning the mechanism of action, efficacy and safety of this novel antidiabetic therapeutic approach.

Filtration and Reabsorption of Glucose by the Kidney
Approximately 180 liters of plasma, which contain ~162g of glucose, are filtered by the glomeruli every day. In normal-glucose-tolerant subjects virtually all of this glucose is completely reabsorbed in the proximal tubule. The maximum glucose transport capacity (Tm) of the proximal tubule, on average, has a value of ~375mg/minute.11 In both the S1 and S3 segments of the proximal tubule, glucose transport is mediated by sodium–glucose co-transporters (SGLTs) and is coupled to sodium reabsorption. The sodium electrochemical gradient generated by active sodium transport provides the energy required for glucose transport. SGLT1 mediates glucose transport in the S3 segment and SGLT2 mediates glucose transport in the S1 segment. As the filtered glucose load is less than 375mg/minute in non-diabetic subjects, all of the filtered glucose is reabsorbed and returned to the circulation (see Figure 1). If the filtered glucose load exceeds 375mg/minute, as often occurs in type 2 diabetes subjects, the Tm is exceeded and all of the glucose in excess of the Tm is excreted in the urine. The plasma glucose concentration at which the filtered glucose load reaches 375mg/minute is called the threshold. When the threshold is exceeded, the glucose excretion rate increases linearly and parallels the filtered load. The reabsorption and excretion curves display a non-linear transition as the Tm for glucose is approached. This ‘rounding’ of the curves is termed splay, and has been explained by heterogeneity in the Tm for individual nephrons and/or glomerulotubular imbalance.11

Normal-glucose-tolerant subjects have a Tm for glucose that is well above the filtered glucose load. This has major survival benefits, since it allows the kidneys to conserve this critical energy source for the brain, which (with the exception of prolonged fasting) can only utilize glucose to generate energy for neuronal function. However, in patients with diabetes this adaptive mechanism becomes maladaptive. In the presence of hyperglycemia, it would be desireable for the kidney to excrete the excess filtered glucose load to restore normoglycemia. In fact, the diabetic kidney has an increased Tm for glucose, thereby minimizing glucosuria and exacerbating the hyperglycemia. When viewed in these terms, it is evident that the kidney contributes to the development and maintenance of hyperglycemia in individuals with diabetes.

It also should be noted that increased glucose uptake in the proximal tubules in subjects with diabetes is accompanied by increased sodium reabsorption, which contributes to extracellular volume expansion and an increase in blood pressure. Based on these pathophysiologic considerations, it follows that development of specific inhibitors of the renal SGLT2 transporter provides a rational and novel approach for the treatment of diabetic patients. The specificity for SGLT2 over SGLT1 transporters, which are present in both the gut and kidney, avoids impaired intestinal glucose absorption and diarrhea. Recent evidence also suggests the SGLT1 transporter in cells of the proximal small intestine may be responsible for generating the signal leading to the release of incretin hormones in response to nutrient ingestion.12

Pharmacological Inhibitors Of Renal Glucose Uptake
In 1886, von Mering demonstrated that ingestion of high doses of phlorizin (>1g), a natural product in the bark of apple trees, produced glucosuria in man.13 Studies in the 1950s and the 1960s demonstrated that the glucosuric action of phlorizin resulted from inhibition of active glucose transport in the apical membrane of the renal proximal tubule.14 Phlorizin competitively inhibits both SGLT1 and SGLT2 in the proximal tubule with a higher affinity (10-fold) for the SGLT2 versus SGLT1 transporter and, when given to normal subjects, produces glucosuria that resembles familial renal glucosuria.15 Despite the efficacy of phlorizin in inhibiting SGLT transporter activity and normalizing the plasma glucose concentration in diabetic animals, low bioavailability (~15%) following oral administration and inhibition of SGLT1 in the gastrointestinal tract negate its clinical usefulnees in subjects with diabetes.16 As a result of these limitations of phlorizin, other compounds with greater bioavalability following oral administration and higher selectivity for SGLT2 compared with SGLT1 have been developed (see Table 1).

Since the SGLT2 gene primarily is expressed in kidney proximal tubules, downregulating SGLT2 gene expression with antisense oliglonucleotides (ASOs) is another approach that has been used to inhibit renal glucose reabsorption.17 Studies in rats, dogs, and monkeys have demonstrated that ASOs decrease renal SGLT2 mRNA expression by ~80% with no significant change in SGLT1 expression and this is accompanied by pronounced glucosuria. Furthermore, a once-weekly injection of ASOs for four to five weeks caused a substantial reduction in plasma glucose concentration and HbA1c without any appreciable side effects. As the ASOs work by reducing the SGLT2 protein content, rather than inhibiting the SGLT2 transporter, they have the potential to cause a much greater reduction in HbA1c.

Inhibition of Renal Glucose Transport Corrects Hyperglycemia—Proof of Concept
Studies performed with phlorizin in 90% pancreatectomized diabetic rats have provided proof of concept for the efficacy of SGLT2 inhibition in the treatment of type 2 diabetes. Chronic phlorizin administration in this insulinopenic type 2 diabetic model18–20 induced glucosuria and normalized both the fasting and fed plasma glucose levels with complete reversal of the insulin resistance. When phlorizin was withdrawn from phlorizin-treated animals, hyperglycemia and insulin resistance returned. Chronic phlorizin treatment also corrected the defects in both first- and second-phase insulin secretion in this diabetic rodent model.20 Similar effects on plasma glucose concentration, insulin resistance, and beta-cell function were observed with selective SGLT2 inhibitors. Studies in animal models of diabetes have demonstrated that T-1095, sergliflozin, and dapagliflozin decrease fasting plasma glucose and the area under plasma glucose concentration curve following glucose administration and improve both insulin sensitivity and beta-cell function.21–23

Familial renal glucosuria has provided assurance of the safety of pharmacological inhibition of SGLT2. Affected individuals with loss-of-function mutations in the gene encoding for the SGLT2 transporter manifest varying degrees of glucosuria (20–200g per day). Despite the large glucosuria, these subjects are asymptomatic with no signs of hypoglycemia.24 These observations provide proof of concept that pharmacological inhibition of SGLT2 is a safe and potentially effective strategy for reducing the plasma glucose concentration in subjects with diabetes. Sodium–Glucose Co-transporter 2 Inhibitors in Type 2 Diabetes Subjects
Clinical trials with dapagliflozin are the most advanced of the SGLT2 inhibitors and two phase III trials have been completed.25,26 In a 14-day study, dapagliflozin (5, 25, and 100mg/day) caused glucosuria (37, 62, and 80g/24 hours, respectively) and significantly decreased the fasting plasma glucose concentration (by 19, 29, and 39mg/dl, respectively) and the incremental area under the glucose curve during an oral glucose tolerance test (OGTT) in subjects with type 2 diabetes.27 In humans, dapagliflozin has a T½ of ~17–18 hours, making it suitable for once-daily administration.28 Dapagliflozin is rapidly absorbed after oral administration, achieving maximal plasma concentrations within two hours. Dapagliflozin is highly protein-bound (97–98%) and renal excretion is low (2–4%). An inert glucuronide conjugate (M15) of dapagliflozin is the major metabolite and dapagliflozin does not inhibit or induce P450 enzymes.

More prolonged treatment (12 weeks) with dapagliflozin reduced HbA1c by ~0.7% without any apparent dose dependency in type 2 diabetes subjects with a baseline HbA1c of 7.8–8%.29 The reduction in HbA1c was similar in magnitude to that observed with metformin, and the reductions in fasting and postprandial plasma glucose concentrations accounted approximately equally for the decline in HbA1c.29 Dapagliflozin-treated diabetic subjects lost between 2.2 and 3.1kg of bodyweight and also experienced a modest reduction in both systolic and diastolic blood pressure. The amount of glucosuria observed with dapagliflozin (50–60g/day) is equivalent to a daily caloric loss of ~200–240 calories per day, which over the course of 12 weeks could explain the 2–3kg weight loss. In a large (n=546) randomized, double-blind, placebo-controlled 24-week trial in metformin-treated type 2 diabetes patients,25 dapagliflozin in doses of 2.5, 5, and 10mg/day decreased the HbA1c by 0.67, 0.70, and 0.84%, respectively, compared with placebo (+0.3%; all p< 0.01). Bodyweight decreased by 2.26, 3.10, and 2.96kg, respectively, compared with controls (-0.87kg) (all p< 0.01). In 274 type 2 diabetes patients controlled by diet and exercise, dapagliflozin in doses of 2.5, 5.0 and 10mg/day reduced HbA1c by 0.58, 0.77, and 0.89% and bodyweight by -3.3, -2.8, and -3.2kg after 24 weeks.26 In the placebo-treated group, HbA1c and bodyweight declined by 0.23% and 2.2kg, respectively (p< 0.001 versus dapagliflozin 5 and 10mg/day). The incidences of urinary tract infection and genital infections were slightly increased with the higher doses (5 and 10mg) of dapagliflozin compared with placebo. There were no clinically relevant changes from baseline in serum creatinine or electrolytes. In a subgroup of 74 diabetes patients with HbA1c of 10.1–12.0%, 24 weeks of dapagliflozin treatment reduced the HbA1c by 2.88% (5mg/day) and 2.66% (10mg/day).26

Two recently completed studies demonstrate the efficacy of dapagliflozin in reducing HbA1c independent of the severity of insulin resistance and beta-cell failure. In one study, Wilding et al. randomized 71 insulin-treated (50units/day) type 2 diabetes patients who also were receiving an insulin sensitizer (metformin and/or thiazolidinedione) to add-on therapy with dapagliflozin (5 and 10mg/day) or placebo.30 The insulin dose was reduced by 50% at the start of therapy, while the insulin sensitizer dose was unchanged. After 12 weeks, the placebo-subtracted declines in HbA1c were 0.70 and 0.78%, respectively (p< 0.01 versus placebo) despite the 50% reduction in insulin dose. The placebo-subtracted reductions in bodyweight were 2.6 and 2.4kg, respectively (p< 0.01 versus placebo), reflecting both the loss of glucose in the urine and reduction in insulin dose. In another study, 151 early-stage (diabetes duration one year) and 58 late-stage (diabetes duration 11 years) type 2 diabetes patients were randomly assigned to 10 or 20mg/day of dapagliflozin for 12 weeks.31 The late-stage diabetic group was in poor glycemic control (HbA1c 8.4%), despite large doses of insulin (>50units/day) plus metformin and a thiazolidinedione. Dapagliflozin caused a comparable decline in HbA1c in both groups. A number of other SGLT2 inhibitors have entered early trials for the treatment of type 2 diabetes. In a phase 1 study, a single dose of sergliflozin (50–500mg) caused a dose-dependent increase in glucosuria in both normal and type 2 diabetes subjects.32,33 The 500mg dose reduced the mean plasma glucose concentration during the OGTT from 18.3mM to 11.2mM.33 More prolonged treatment (14 days) with sergliflozin also induced dose-dependent glucosuria with modest weight loss. Interestingly, SGLT2 inhibition was accompanied by an increase in plasma glucagon-like peptide 1 (GLP-1) concentration and weight loss of 1.5kg.33 In a double-blind, placebo-controlled, dose-ranging study in 451 metformin-treated type 2 diabetes subjects, canagliflozin in doses of 50, 100, 200, and 300mg/day for 12 weeks reduced HbA1c by 0.7–0.9% from baseline and by 0.5–0.7% versus placebo in association with weight loss of 1.3–2.3kg.34 The 300mg/day dose appeared to be slightly more effective then the lower doses. In a 16-day trial, canagliflozin was shown to improve beta-cell function in type 2 diabetes patients using a model-based method to calculate insulin secretion.35 In a small study involving 29 type 2 diabetic subjects sub-optimally controlled (HbA1c 8.4%) with insulin, addition of canagliflozin at 100 and 300mg/day for 28 days reduced the HbA1c by 0.7% and 0.9%, respectively.36

Similar results have been observed with other SGLT2 inhibitors. In a four-week study, BI 10773 at a dose 100mg/day increased urinary glucose excretion by 74.3g per day.37 In a 12-week double-blind study, 361 Japenese type 2 diabetes subjects treated with ASP1941 at doses ranging from 12.5 to 100mg/day experienced a 0.9% reduction in HbA1c at the highest doses (50 and 100mg/day).38 Bodyweight was also dose-dependently reduced by up to 2kg in the 100mg/day dose. In a phase 2A study, LX4211, which inhibits SGLT2 and to a lesser extent SGLT1, at doses of 150 and 300mg/day reduced HbA1c by 1.2% but starting HbA1c (8.2–8.5%) was higher than in most other studies and the placebo decreased the HbA1c by 0.5%.39 Remogliflozin belongs to a different family of SGLT2 inhibitors and has a structural scaffold differing from that of pholirzin.40 Remogliflozin caused a dose-dependent glucosuria and, in 35 patients with drug-naïve type 2 diabetes, 12 days of treatment with resulted in a decrease in fasting plasma glucose concentration (~30mg/dl), bodyweight (2.6kg), and blood press
re (~8mmHg).41

It is noteworthy that the increase in urine glucose excretion (60–80g/day) observed with all SGLT2 an inhibitors currently in clinical trials, even with maximal doses, represents an inhibition of less than 50% of the filtered glucose load. The failure to observe a greater inhibition of renal glucose absorption is unclear but could be explained by: inability of the SGLT2 inhibitor to reach the SGLT2 transporters because of their anatomical location; competitive inhibition that progressively raises the local concentration of glucose at the site of the SGLT2 transporter, thus reducing its effectiveness; insufficiently high drug concentrations in the tubular lumen to inhibit the SGLT2 transporter; glucose transporters other than SGLT2 in man are responsible for a much greater fraction of glucose reabsorption than previously appreciated; and upregulation of the SGLT1 or other glucose transporters offsets the glucosuric effect of SGLT2 inhibitors. The latter seems unlikely since the magnitude of glucosuria on days one to three versus day 14 after the start of dapagliflozin is similar.27

No SGLT2 inhibitor has been studied in patients with diabetes and reduced glomerular filitration rate (GFR). Because of the reduction in GFR (reduced filtered glucose load) and/or tubular damage, it is likely that the efficacy of SGLT2 inhibitors will be reduced in individuals with reduced GRF. This needs to be examined before this class of drugs can be recommended in patients with diabetes and reduced GFR.

Finally, it remains to be determined whether oral SGLT2 inhibitors cause glucosuria by inhibiting the Tm for glucose and/or increasing the glucose splay. One study in rodents with sergliflozin indicates a reduction in Tm without change in the glucose splay.22 We believe that neither of these two explanations (reduced Tm or increased splay) can satisfactorily explain the marked glucosuria induced by the SGLT2 inhibitors in normal glucose-tolerant individuals with a fasting plasma glucose of 80–90mg/dl. Rather, we believe that the SGLT2 inhibitors inhibit a constant percentage of the filtered glucose load at all plasma glucose concentrations. At high plasma glucose concentrations, this would result in a greater amount of glucosuria than at low plasma glucose concentrations, although the fractional glucose inhibition would be similar. This does not exclude a concomitant reduction in the glucose Tm and is, in fact, most consistent with the effect of sergliflozin on renal glucose excretion.22 Sodium–Glucose Co-transporter 2 Inhibitors and Diabetic Nephropathy
Hyperglycemia is the principal risk factor for diabetic microvascular complications (retinopathy, nephropathy, and neuropathy), and improved glycemic control—no matter how achieved—would be expected to reduce the risk of microvascular complications in subjects with type 2 diabetes.4,5 As a result of the important role of enhanced glucose reabsorption in the proximal tubule in altering renal hemodynamics and the development of diabetic nephropathy,42,43 inhibition of renal glucose absorption with an SGLT2 inhibitor might be expected to have an additional beneficial reno-protective action beyond its glucose-lowering effect. The increased filtered glucose load in diabetes results in increased glucose and sodium reabsorption by the SGLT2 transporter in the proximal tubule.44,45 Some investigators43 have postulated that the primary abnormality resides at the level of the proximal tubule and is characterized by an intrinsic increase in glucose/sodium reabsorption because of a generalized increase in kidney size and renal (both glomerular and tubular) hypertrophy. In either case, enhanced sodium reabsorption in the proximal tubule leads to a reduction in sodium delivery to the juxtaglomerular apparatus and activates the tubuloglomerular feedback reflex, resulting in vasodilation, elevated intraglomerular pressure and increased glomerular filtration rate until distal salt delivery returns to its normal set point.46 Renal hyperfiltration and increased kidney size are early characteristic changes of diabetic nephropathy47 and can be reversed by six weeks of intensive insulin therapy that normalizes plasma glucose concentration.47

Therefore, SGLT2 inhibitors could have a dual effect to prevent renal hyperfiltration: normalization of the plasma glucose concentration with reversal of renal hypertrophy, decreased intraglomerular pressure/renal hyperfiltration, and reduced filtered glucose load; increased sodium delivery to the distal tubule with inhibition of the tubuloglomerular feedback reflex. With regard to this, it is noteworthy that chronic T-1095 administration decreased HbA1c levels in mice with diabetes and stopped the progression of diabetic nephropathy with prevention of proteinuria and expansion of glomerular mesangial area.48

Non-glycemic Benefits
In addition the beneficial effects related to improved glycemic control, SGLT2 inhibitors have a number of non-glycemic effects that make them desirable agents as monotherapy and for combination treatment with other antidiabetic agents. Weight gain is a major problem with currently available antidiabetes medications including sulfonylureas, thiazolidinediones, and insulin. The urinary loss of 60–80g of glucose per day equates to 240–320 calories/day or 2–3lbs/month if this caloric deficit is not offset by an increase in caloric intake. Consistent with this, 12–24 weeks of treatment with dapagliflozin has been associated with weight losses of 2–3kg. A consistent finding in all dapagliflozin studies has been a reduction blood pressure of 4–5/2–3mmHg.29 Although this has been attributed to the mild fluid/sodium deficit that occurs during the first few days of dapagliflozin treatment,27,29 an equally plausible explanation is local inhibition of the renin–angiotensin system secondary to enhanced sodium delivery to the juxtaglomerular apparatus.42,43 Consistent with the inhibition of sodium-coupled uric acid reabsorption in the proximal tubule, a decrease in serum uric acid concentration has been observed in diabetic patients treated with dapagliflozin.43 The effect of dapagliflozin on plasma lipid levels has yet to be published.27,29Safety
The pharmacological properties of SGLT2 inhibitors suggest that they should have a good safety profile. As a result of their high selectivity for the SGLT2 transporter, no inhibition of the SGLT1 transporter in the intestinal mucosa is anticipated and gastrointestinal side effects have not been observed. Furthermore, because subjects homozygous for mutations in the SGLT2 gene generally are asymptomatic despite large amounts of glucosuria (>50–100g per 24 hours), pharmacological inhibition of SGLT2 would not be expected to cause polyuria, nocturia, or volume contraction, and, in fact, these side effects have not been observed in clinical trials. When dapagliflozin has been administered to humans for up to 12–24 weeks, urine volume increased only modestly (200–400ml/day) during the first two to three days after initiation of therapy and excessive urine losses of sodium, potassium, and other electrolytes was not observed.29 Consistent with mild volume contract, a small rise in hematocrit (1–2 volume %) and plasma creatinine to urea nitrogen ratio have been observed. Plasma electrolyte concentrations did not change following dapagliflozin.27,29 As stated previously, modest reductions in both systolic and diastolic blood pressure have been observed in type 2 diabetes patients.29

Lastly, because SGLT2 inhibitors have no effect on the glucose counter-regulatory mechanisms, hypoglycemia is not anticipated. In animals with and without diabetes and humans with diabetes, the administration of SGLT2 inhibitors was not associated with hypoglycemia.27,29 Although the SGLT2 inhibitors promote glucosuria and this could result in an increased incidence of urinary tract infections, patients with diabetes already have significant glucosuria and it remains to be determined whether the additional glucosuria will promote bacterial growth. Since chronic hyperglycemia inhibits phagocytic activity by white blood cells, it is possible that any increased risk of bacterial urinary tract infection would be offset by the improved phagocytic activity. The incidences of vulva-vaginitis and balanitis are increased approximately twofold.25,26,29,30 SGLT2 inhibitors have not been shown to have any deleterious effect on renal function as manifested by a rise in serum creatinine or development of albuminuria or tubular proteinuria in patients with diabetes and normal GFR. However, studies in individuals with a reduced GFR will be required to demonstrate the safety, as well as efficacy, in this group.

Summary and Conclusion
Current data in experimental animals and humans indicate that inhibition of the SGLT2 transporter is an effective and novel strategy to control the plasma glucose concentration in type 2 diabetes subjects. In type 2 diabetes patients, dapagliflozin—the most clinically advanced of the SLGT2 inhibitors—has demonstrated a good safety profile, modest weight loss, and HbA1c reduction of ~0.7–0.8% with a starting HbA1c of ~8.0%. As SGLT2 inhibitors have a distinct mechanism of action that is independent of insulin secretion or the presence of insulin resistance, the efficacy of this class of drugs is not anticipated to decline with progressive beta cell failure or in the presence of severe insulin resistance. Furthermore, this class of drugs can be used in combination with all other antidiabetic medications with anticipated additive efficacy on glycemic control. The SGLT2 inhibitors also are effective as monotherapy in newly diagnosed diabetic patients. To the extent that glucotoxicity contributes to the demise in beta cell function in subjects with impaired glucose tolerance (IGT) or impaired fasting glucose (IFG), these drugs may also prove useful in the treatment of ‘pre-diabetes’. Currently available data indicate that the SGLT2 inhibitors have a good safety profile. In addition, the asymptomatic clinical presentation of subjects with familial renal glucosuria, despite multiple generations of the disease, has documented the long-term safety of pharmacological inhibition of the SGLT2 transporter.

Article Information:

References

  1. Schalkwijk CG, Stehouwer CD, Vascular complications in diabetes mellitus: the role of endothelial dysfunction, Clin Sci (Lond), 2005;109:143–59.
  2. He Z, King GL, Microvascular complications of diabetes, Endocrinol Metab Clin North Am, 2004;33:215–38.
  3. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 1993;329: 977–86.
  4. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 1998;352:837–53.
  5. DeFronzo RA, Banting Lecture: From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus, Diabetes, 2009;58:773–95.
  6. Rossetti L, Giaccari A, DeFronzo RA, Glucose toxicity, Diabetes Care, 1990;13:610–30.
  7. The American Diabetes Association, Standards of medical care in diabetes—2007, Diabetes Care, 2007;30(Suppl. 1): S4–41.
  8. Qaseem A, Vijan S, Snow V, et al., Clinical Efficacy Assessment Subcommittee of the American College of Physicians, Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians, Ann Int Med, 2007;147:417–22.
  9. Rodbard HW, Davidson JA, Garber AJ, et al., AACE/ACE Consensus Statement. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: an algorithm for glycemic control, Endocr Pract, 2009;15:540–59.
  10. Nathan DM, Buse JB, Davidson MB, et al., Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: Update regarding the thiazolidinediones, Diabetologia, 2008;51:8–11.
  11. Valtin H, Tubular reabsorption. In: Renal Function, Boston: Little, Brown and Company, 1983.
  12. Gribble FM, Williams L, Simpson AK, Reimann F, A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line, Diabetes, 2003;52:1147–54.
  13. von Mering J, Ueber kunstlichen diabetes, Centralbl Med Wiss, 1886;22:531.
  14. Vick HD, Deidrich DF, Re-evaluation of renal tubular glucose transport inhibition by phlorizin analogs, Am J Physiol, 1973;224:552–7.
  15. Chassis H, Jolliffe N, Smith H, The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine, and urea by man, J Clin Invest, 1933;12:1083–9.
  16. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J, Phlorizin: a review, Diabetes Metab Res Rev, 2005;21:31–8.
  17. Bhanot S, Murray SF, Booten SL, et al., ISIS 388626, an SGLT2 antisense drug, causes robust and sustained glucosuria in multiple species and is safe and well-tolerated, Diabetes, 2009;58(Suppl. 1):A328.
  18. Kahn BB, DeFronzo RA, Cushman SW, Rossetti L, Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression, J Clin Invest, 1999;87: 561–70.
  19. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA, Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats, J Clin Invest, 1987;79:1510–5.
  20. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA, Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats, J Clin Invest, 1987;80:1037–44.
  21. Oku A, Ueta K, Nawano M, et al., Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats, Eur J Pharmacol, 2000;391:183–92.
  22. Katsuno K, Fujimori Y, Takemura Y, et al., Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level, J Pharmacol Exp Ther, 2007;320:323–30.
  23. Han S, Hagan DL, Taylor JR, et al., Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats, Diabetes, 2008;57:1723–9.
  24. Santer R, Kinner M, Lassen CL, et al., Molecular analysis of the SGLT2 gene in patients with renal glucosuria, J Am Soc Nephrol, 2003;14:2873–82.
  25. Bailey CJ, Gross JL, Pieter A, Bastien A, List JF, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin; a randomized, double-blind, placebo-controlled trail, Lancet, 2010;375:2223–33.
  26. Ferrannini E, Ramos SJ, Tang W, et al., Dapagliflozin monotherapy in T2DM patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, multicenter phase III trial, (Late-Breaking Abstract) International Diabetes Federation World Congress, Montreal, Canada, November, 2009.
  27. Komoroski B, Vachharajani N, Feng Y, et al., Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus, Clin Pharmacol Ther, 2009;85:513.
  28. Obermeier M, Yao M, Khanna A, et al., In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium–glucose cotransporter type II inhibitor, in animals and humans, Amer Soc Pharm Exp Ther, 2010;38:405–14.
  29. List J, Woo V, Morales E, et al., Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes, Diabetes Care, 2009;32:650–7.
  30. Wilding JPH, Norwood P, Tjoen C, et al., A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Applicability of a novel insulin-independent treatment, Diabetes Care, 2009;32:1656–62.
  31. Zhang L, Feng Y, List J, et al., Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight, Diab Obesity Metab, 2010;12:510–6.
  32. Hussey E, Clark R, Amin D, et al., Early clinical studies to assess safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of sergliflozin, a novel inhibitor of renal glucose reabsorption in healthy volunteers and subjects with type 2 diabetes mellitus, Diabetes, 2007;56(Suppl. 1):A189.
  33. Hussey E, Dobbins R, Stolz R, et al., A double-blind randomized repeat dose study to assess safety, tolerability, pharmacokineticks and pharmacodynamics of three times daily dosing of sergliflozin, a novel inhibitor of renal glucose reabsorption in healthy overweight and obese subjects, Diabetes, 2007;56(Suppl. 1):A491.
  34. Rosensotck J, Arbit D, Usiskin K, et al., Canagliflozin an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with type 2 diabetes (T2D) on metformin, Diabetes, 2010;59(Suppl. 1):A21.
  35. Polidori D, Zhao Y, Sha S, Canovatchel W, Canagliflozin treatment improves beta cell function in subject with type 2 diabetes, Diabetes, 2010;59(Suppl. 1):A176.
  36. Schwartz S, Morrow L, Hompesch M, et al., Canagliflozine improves glycemic control in subjects with type 2 diabetes (T2D) not optimally controlled on stable doses of insulin, Diabetes, 2010;59(Suppl. 1):564P.
  37. Koiwai K, Seman L, Yamamura N, et al., Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of BI 10773, a sodium-glucose co-transporter inhibitor (SGLT2), in Japanese healthy volunteers, Diabetes, 2010;59(Suppl. 1):2175PO.
  38. Kashiwagi A, Utsuno A, Kazuta K, et al., ASP1941, a novel, selective SGLT2 inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes mellitus, Diabetes, 2010;59(Suppl. 1):A21.
  39. Freiman J, Ruff DA, Frazier KS, et al., LX4211, a dual SGLT2/SGLT1 inhibtor, shows rapid and significant improvements in glycemic control over 28 days in patients with type 2 diabetes (T2DM), Diabetes, 2010;59(Suppl. 1), late breaking abstract.
  40. Fujimori Y, Katsuno K, Nakashima I, et al., Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models, J Pharmacol Exp Ther, 2008;327:268–76.
  41. Dobbins RL, Kapur A, Kapitza C, et al., Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2) reduces serum glucose in type 2 diabetes mellitus (T2DM) patients, Diabetes, 2009;58 (Suppl. 1):A573.
  42. Vallon V, Richter K, Blantz RC, et al., Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption, J Am Soc Nephrol, 1999;10: 2569–76.
  43. Thomson SC, Vallon V, Blantz RC, Kidney function in early diabetes: the tubular hypothesis of glomerular filtration, Am J Physiol, 2004;286:F8–18.
  44. Noonan WT, Shapiro VM, Banks RO, Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats, Life Sci, 2001;68: 2967–77.
  45. Dominguez JH, Camp K, Maianu L, et al., Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats, Am J Physiol, 1994;266:F283–90.
  46. Nelson RG, Bennett PH, Beck GJ, et al., Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group, N Engl J Med, 1996;335:1636–42.
  47. Tuttle KR, Bruton JL, Perusek MC, et al., Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus, N Engl J Med, 1991;324:1626–32.
  48. Arakawa K, Ishihara T, Oku A, et al., Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095, Br J Pharmacol, 2001;132:578–86.
  49. Bickel M, Brummerhop H, Frick W, et al., Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats, Arzneimittelforschung, 2008;58:574–80.

Further Resources

Share this Article
Related Content In Diabetes
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72